Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment response in patients with schizophrenia

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Pharmacogenetics & Genomics

• Publication date

  2015-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/FPC.0000000000000122PMID 25714000
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 5-HT2A receptor promoter polymorphism, -1438G/A and negative symptom response to olanzapine in schizophrenia.

  2025cited by this paper
• A contribution of novel CNVs to schizophrenia from a genome-wide study of 41,321 subjects: CNV Analysis Group and the Schizophrenia Working Group of the Psychiatric Genomics Consortium

  2016cited by this paper
• Biological Insights From 108 Schizophrenia-Associated Genetic Loci

  2014cited by this paper
• SULT4A1 haplotype: conflicting results on its role as a biomarker of antipsychotic response.

  2014cited by this paper
• Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment

  2013cited by this paper
• Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis.

  2013cited by this paper
• Neuregulin-1 signalling and antipsychotic treatment

  2013cited by this paper
• COMT, neuropsychological function and brain structure in schizophrenia: a systematic review and neurobiological interpretation.

  2013cited by this paper
• Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis

  2013cited by this paper
• GWAS meta analysis identifies TSNARE1 as a novel Schizophrenia / Bipolar susceptibility locus

  2013cited by this paper
• Investigation of allelic heterogeneity of the CCK‐A receptor gene in paranoid schizophrenia

  2012cited by this paper
• A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia.

  2012cited by this paper
• Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy

  2012cited by this paper
• Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults

  2012cited by this paper
• Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes.

  2012cited by this paper
• Antipsychotic treatment and neuregulin 1-ErbB4 signalling in schizophrenia.

  2011cited by this paper
• [Expressional changes of neuregulin-1 gene mRNA in peripheral blood from schizophrenia patients].

  2011cited by this paper
• Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial

  2011cited by this paper
• Common variants at VRK2 and TCF4 conferring risk of schizophrenia.

  2011cited by this paper
• A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.

  2011cited by this paper
• Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia

  2011cited by this paper
• New from NPG: Genome-wide association study identifies five new schizophrenia loci

  2011cited by this paper
• A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

  2010cited by this paper
• A Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of 3 Doses of Paliperidone Palmitate in Adults With Acutely Exacerbated Schizophrenia

  2010cited by this paper
• Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

  2010cited by this paper
• Decreased Neuregulin 1 C-terminal fragment in Brodmann's area 6 of patients with schizophrenia.

  2010cited by this paper
• Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study.

  2010cited by this paper
• D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.

  2010cited by this paper
• Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine.

  2009cited by this paper
• [Association analysis of neuregulin 1 gene polymorphism with schizophrenia in Chinese Han population].

  2009cited by this paper
• Neuregulin 1 and age of onset in the major psychoses

  2009cited by this paper
• Akt/GSK3 signaling in the action of psychotropic drugs.

  2009cited by this paper
• Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia

  2009cited by this paper
• HTR2A A-1438G/T102C polymorphisms predict negative symptoms performance upon aripiprazole treatment in schizophrenic patients

  2009cited by this paper
• Potential etiologic and functional implications of genome-wide association loci for human diseases and traits

  2009cited by this paper
• Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

  2009cited by this paper
• Understanding the Role of DISC1 in Psychiatric Disease and during Normal Development

  2009cited by this paper
• Common variants conferring risk of schizophrenia

  2009cited by this paper
• Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia.

  2009cited by this paper
• Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study

  2009cited by this paper
• Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system

  2009cited by this paper
• Effects of the Dopamine D3 Receptor (DRD3) Gene Polymorphisms on Risperidone Response: A Pharmacogenetic Study

  2008cited by this paper
• Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting

  2008cited by this paper
• Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene

  2008cited by this paper
• Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension.

  2008cited by this paper
• Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies.

  2008cited by this paper
• Association between Polymorphisms in the Vesicular Monoamine Transporter 1 Gene (VMAT1/SLC18A1) on Chromosome 8p and Schizophrenia

  2008cited by this paper
• Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.

  2008cited by this paper
• Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology.

  2008cited by this paper
• Association and interaction analyses of NRG1 and ERBB4 genes with schizophrenia in a Japanese population

  2008cited by this paper
• Neuregulin 1 in neural development, synaptic plasticity and schizophrenia

  2008cited by this paper
• Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database

  2008cited by this paper
• Chronic antipsychotic drug administration alters the expression of neuregulin 1beta, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus.

  2008cited by this paper
• The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients.

  2007cited by this paper
• Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia

  2007cited by this paper
• Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study.

  2007cited by this paper
• A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1

  2007cited by this paper
• Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.

  2007cited by this paper
• Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial.

  2007cited by this paper
• An update on the genetics of schizophrenia

  2006cited by this paper
• Association of the NRG1 gene and schizophrenia: a meta-analysis

  2006cited by this paper
• Haplotypic association spanning the 22q11.21 genes COMT and ARVCF with schizophrenia

  2005cited by this paper
• Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.

  2005cited by this paper
• Dopamine D3 Receptor Ser9Gly Polymorphism and Risperidone Response

  2005cited by this paper
• Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.

  2005cited by this paper
• The C/C genotype of the C957T polymorphism of the dopamine D2 receptor is associated with schizophrenia.

  2005cited by this paper
• Role of dopamine D3 receptor (DRD3) and dopamine transporter (DAT) polymorphism in cognitive dysfunctions and therapeutic response to atypical antipsychotics in patients with schizophrenia

  2004cited by this paper
• An excitement subscale of the Positive and Negative Syndrome Scale.

  2004cited by this paper
• Neuregulin 1 and susceptibility to schizophrenia.

  2002cited by this paper
• Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.

  2002cited by this paper
• Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D(2) receptor gene.

  2001cited by this paper
• Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response.

  1998cited by this paper
• Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia.

  1997cited by this paper
• The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

  1997cited by this paper
• Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia

  1997cited by this paper
• A Novel Juxtamembrane Domain Isoform of HER4/ErbB4

  1997cited by this paper
• In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used.

  1995cited by this paper
• Serveur Académique Lausannois SERVAL serval.unil.ch

  year unknowncited by this paper

• Pharmacogenetic study of antipsychotic–induced lipid and BMI changes in Chinese schizophrenia patients: A Genome-Wide Association Study

  2024cites this paper
• Pharmacogenetics of antipsychotics: Clinical utility and implementation.

  2020cites this paper
• Pharmacogenomics in Psychiatric Disorders

  2019cites this paper
• Genetic variations in the ADCK1 gene predict paliperidone palmitate efficacy in Han Chinese patients with schizophrenia

  2018cites this paper
• Clinical improvement, relapse and treatment adherence with paliperidone palmitate 1-month formulation: 1-year treatment in a naturalistic outpatient setting

  2018cites this paper
• New findings in pharmacogenetics of schizophrenia

  2018cites this paper
• Genetic recovery of ErbB4 in adulthood partially restores brain functions in null mice

  2018cites this paper
• Multi-scale analysis of schizophrenia risk genes, brain structure, and clinical symptoms reveals integrative clues for subtyping schizophrenia patients

  2018cites this paper
• Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications

  2018cites this paper
• Current pharmacotherapy for obesity

  2018cites this paper
• Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: A meta-analysis in Asian population

  2017cites this paper
• Neuregulin-1 and schizophrenia in the genome-wide association study era.

  2016cites this paper
• Paliperidone Palmitate Treatment in Outpatient Care Setting: A Naturalistic Study.

  2016cites this paper
• Decreased plasma levels of neureglin-1 in drug naïve patients and chronic patients with schizophrenia.

  2015cites this paper
• HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis

  2015cites this paper